An Immune-Related lncRNA Signature to Predict the Biochemical Recurrence and Immune Landscape in Prostate Cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Mccormick B, Mahmoud A, Williams S, Davis J. Biochemical recurrence after radical prostatectomy: current status of its use as a treatment endpoint and early management strategies. Indian J Urol. 2019;35(1):6–17. doi:10.4103/iju.IJU_355_18
   PubMed Web of Science ®Google Scholar
• Carroll PH, Mohler JL. NCCN guidelines updates: prostate cancer and prostate cancer early detection. J Natl Compr Canc Netw. 2018;16(5S):620–623. doi:10.6004/jnccn.2018.0036
   PubMed Web of Science ®Google Scholar
• Montironi R, Mazzucchelli R, Scarpelli M, et al. Prostate carcinoma II: prognostic factors in prostate needle biopsies. BJU Int. 2006;97(3):492–497. doi:10.1111/j.1464-410X.2006.05973.x
   PubMed Web of Science ®Google Scholar
• Kreuz M, Otto DJ, Fuessel S, et al. ProstaTrend—a multivariable prognostic RNA expression score for aggressive prostate cancer. Eur Urol. 2020;78(3):452–459. doi:10.1016/j.eururo.2020.06.001
   PubMed Web of Science ®Google Scholar
• Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74–80. doi:10.1126/science.aaa6204
   PubMed Web of Science ®Google Scholar
• Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298–312. doi:10.1038/s41568-021-00339-z
   PubMed Web of Science ®Google Scholar
• Schaafsma E, Fugle CM, Wang X, Cheng C. Pan-cancer association of HLA gene expression with cancer prognosis and immunotherapy efficacy. Br J Cancer. 2021;125(3):422–432. doi:10.1038/s41416-021-01400-2
   PubMed Web of Science ®Google Scholar
• Wickenhauser C, Bethmann D, Kappler M, et al. Tumor microenvironment, HLA class I and APM expression in HPV-negative oral squamous cell carcinoma. Cancers. 2021;13(4):620. doi:10.3390/cancers13040620
   PubMed Web of Science ®Google Scholar
• Ladanyi A, Timar J. Immunologic and immunogenomic aspects of tumor progression. Semin Cancer Biol. 2020;60:249–261. doi:10.1016/j.semcancer.2019.08.011
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.101
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28(6):690–714. doi:10.1016/j.ccell.2015.10.012
   PubMed Web of Science ®Google Scholar
• Cech TR, Steitz JA. The noncoding RNA revolution—trashing old rules to forge new ones. Cell. 2014;157(1):77–94. doi:10.1016/j.cell.2014.03.008
   PubMed Web of Science ®Google Scholar
• Ulitsky I, Bartel DP. LincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46. doi:10.1016/j.cell.2013.06.020
   PubMed Web of Science ®Google Scholar
• Cai P, Otten ABC, Cheng B, et al. A genome-wide long noncoding RNA CRISPRi screen identifies PRANCR as a novel regulator of epidermal homeostasis. Genome Res. 2020;30(1):22–34. doi:10.1101/gr.251561.119
   PubMed Web of Science ®Google Scholar
• Marchese FP, Raimondi I, Huarte M. The multidimensional mechanisms of long noncoding RNA function. Genome Biol. 2017;18(1):206. doi:10.1186/s13059-017-1348-2
   PubMed Web of Science ®Google Scholar
• Lee S, Kopp F, Chang T, et al. Noncoding RNA NORAD regulates genomic stability by sequestering PUMILIO proteins. Cell. 2016;164(1–2):69–80. doi:10.1016/j.cell.2015.12.017
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang J, Liu X, et al. The LINC01138 drives malignancies via activating arginine methyltransferase 5 in hepatocellular carcinoma. Nat Commun. 2018;9(1):1572. doi:10.1038/s41467-018-04006-0
   PubMed Web of Science ®Google Scholar
• Martínez-Terroba E, Dimitrova N. Long noncoding RNA amplified in lung cancer rewires cancer pathways. J Cell Biol. 2020;219(9). doi:10.1083/jcb.202007098
   PubMed Web of Science ®Google Scholar
• Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463. doi:10.1016/j.ccell.2016.03.010
   PubMed Web of Science ®Google Scholar
• Vallino L, Ferraresi A, Vidoni C, et al. Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: in silico analysis and literature review of the anti-cancer pathways involved. J Tradit Complement Med. 2020;10(3):217–229. doi:10.1016/j.jtcme.2020.02.006
   PubMedGoogle Scholar
• Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962–972. doi:10.1038/ni.3771
   PubMed Web of Science ®Google Scholar
• Atianand MK, Caffrey DR, Fitzgerald KA. Immunobiology of long noncoding RNAs. Annu Rev Immunol. 2017;35(1):177–198. doi:10.1146/annurev-immunol-041015-055459
   PubMed Web of Science ®Google Scholar
• Wang L, Felts SJ, Van Keulen VP, et al. Integrative genome-wide analysis of long noncoding RNAs in diverse immune cell types of melanoma patients. Cancer Res. 2018;78(15):4411–4423. doi:10.1158/0008-5472.CAN-18-0529
   PubMed Web of Science ®Google Scholar
• de Lima DS, Cardozo LE, Maracaja-Coutinho V, et al. Long noncoding RNAs are involved in multiple immunological pathways in response to vaccination. Proc Natl Acad Sci UsA. 2019;116(34):17121–17126. doi:10.1073/pnas.1822046116
   PubMed Web of Science ®Google Scholar
• Yu AD, Wang Z, Morris KV. Long noncoding RNAs: a potent source of regulation in immunity and disease. Immunol Cell Biol. 2015;93(3):277–283. doi:10.1038/icb.2015.2
   PubMed Web of Science ®Google Scholar
• Sun Z, Jing C, Xiao C, Li T. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for kidney renal clear cell carcinoma. Front Oncol. 2020;10:1430. doi:10.3389/fonc.2020.01430
   PubMed Web of Science ®Google Scholar
• Zhu T, Ma Z, Wang H, et al. Immune-related long non-coding RNA signature and clinical nomogram to evaluate survival of patients suffering esophageal squamous cell carcinoma. Front Cell Dev Biol. 2021;9:641960. doi:10.3389/fcell.2021.641960
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Kassambara A, Kosinski M, Biecek P, Fabian S. Package ‘survminer’. In: Drawing Survival Curves Using ‘Ggplot2ʹ(R Package Version 03 1); 2017.
   Google Scholar
• Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747–1756. doi:10.1101/gr.239244.118
   PubMed Web of Science ®Google Scholar
• Yi M, Nissley DV, Mccormick F, Stephens RM. SsGSEA score-based ras dependency indexes derived from gene expression data reveal potential ras addiction mechanisms with possible clinical implications. Sci Rep. 2020;10(1):1–16.
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Wickham H. Ggplot2. Wiley Interdiscip Rev Comput Stat. 2011;3(2):180–185. doi:10.1002/wics.147
   Google Scholar
• Team RC. R: a language and environment for statistical computing; 2013.
   Google Scholar
• Sartor O, de Bono JS, Longo DL. Metastatic prostate cancer. New Engl J Med. 2018;378(7):645–657. doi:10.1056/NEJMra1701695
   PubMed Web of Science ®Google Scholar
• Froehner M, Koch R, Graefen M, et al. Re: Nicolas Mottet, Roderick C.N. van den Bergh, Erik Briers, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79:243–62. Eur Urol. 2021;79(5):e138. doi:10.1016/j.eururo.2021.02.005
   PubMed Web of Science ®Google Scholar
• Helleday T. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations. Ann Oncol. 2016;27(5):755–757. doi:10.1093/annonc/mdw048
   PubMed Web of Science ®Google Scholar
• Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. New Engl J Med. 2020;382(25):2465–2468. doi:10.1056/NEJMsb2000250
   PubMed Web of Science ®Google Scholar
• Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. doi:10.1038/s41572-020-00243-0
   PubMed Web of Science ®Google Scholar
• Wang Z, Leushkin E, Liechti A, et al. Transcriptome and translatome co-evolution in mammals. Nature. 2020;588(7839):642–647. doi:10.1038/s41586-020-2899-z
   PubMed Web of Science ®Google Scholar
• Cheng T, Huang S. Roles of non-coding RNAs in cervical cancer metastasis. Front Oncol. 2021;11:646192. doi:10.3389/fonc.2021.646192
   PubMed Web of Science ®Google Scholar
• Parker KA, Robinson NJ, Schiemann WP. The role of RNA processing and regulation in metastatic dormancy. Semin Cancer Biol. 2021. doi:10.1016/j.semcancer.2021.03.020
   Web of Science ®Google Scholar
• Zhang C, Liang Y, Zhang C, et al. The novel role and function of LINC01235 in metastasis of gastric cancer cells by inducing epithelial-mesenchymal transition. Genomics. 2021;113(3):1504–1513. doi:10.1016/j.ygeno.2021.03.027
   PubMed Web of Science ®Google Scholar
• Miao C, Bai L, Yang Y, Huang J. Dysregulation of lncRNAs in rheumatoid arthritis: biomarkers, pathogenesis and potential therapeutic targets. Front Pharmacol. 2021;12:652751. doi:10.3389/fphar.2021.652751
   PubMed Web of Science ®Google Scholar
• Mu L, Ding K, Tu R, Yang W. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma. J Transl Med. 2021;19(1):127. doi:10.1186/s12967-021-02800-x
   PubMed Web of Science ®Google Scholar
• Yang L, Li A, Liu F, et al. Immune profiling reveals molecular classification and characteristic in urothelial bladder cancer. Front Cell Dev Biol. 2021;9:596484. doi:10.3389/fcell.2021.596484
   PubMed Web of Science ®Google Scholar
• Yan Y, Mao X, Zhang Q, et al. Molecular mechanisms, immune cell infiltration, and potential drugs for prostate cancer. Cancer Biomark. 2021:1–10. doi:10.3233/CBM-200939.
   Web of Science ®Google Scholar
• Shao N, Tang H, Mi Y, Zhu Y, Wan F, Ye D. A novel gene signature to predict immune infiltration and outcome in patients with prostate cancer. Oncoimmunology. 2020;9(1):1762473. doi:10.1080/2162402X.2020.1762473
   PubMed Web of Science ®Google Scholar
• Wang Q, Ye Y, Yu H, et al. Immune checkpoint-related serum proteins and genetic variants predict outcomes of localized prostate cancer, a cohort study. Cancer Immunol Immunother. 2021;70(3):701–712. doi:10.1007/s00262-020-02718-1
   PubMed Web of Science ®Google Scholar
• Qu L, Wang Z, Chen Q, et al. Prognostic value of a long non-coding RNA signature in localized clear cell renal cell carcinoma. Eur Urol. 2018;74(6):756–763. doi:10.1016/j.eururo.2018.07.032
   PubMed Web of Science ®Google Scholar
• Weiner AB, Vidotto T, Liu Y, et al. Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes. Nat Commun. 2021;12(1):935. doi:10.1038/s41467-021-21245-w
   PubMed Web of Science ®Google Scholar
• Subudhi SK, Vence L, Zhao H, et al. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med. 2020;12(537):z3577. doi:10.1126/scitranslmed.aaz3577
   Web of Science ®Google Scholar
• Galon J. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964. doi:10.1126/science.1129139
   PubMed Web of Science ®Google Scholar
• Nielsen JS, Sahota RA, Milne K, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27−memory phenotype and together with CD8+ t cells promote favorable prognosis in ovarian cancer. Clin Cancer Res. 2012;18(12):3281–3292. doi:10.1158/1078-0432.CCR-12-0234
   PubMed Web of Science ®Google Scholar
• Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556–560. doi:10.1038/s41586-019-1906-8
   PubMed Web of Science ®Google Scholar
• de Bono JS, Fleming MT, Wang JS, et al. Phase I trial of MEDI3726, a prostate-specific membrane antigen-targeted antibody-drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide. Clin Cancer Res. 2021:2020–4528. doi:10.1158/1078-0432.CCR-20-4528.
   Web of Science ®Google Scholar
• Cha H, Lee JH, Ponnazhagan S. Revisiting immunotherapy: a focus on prostate cancer. Cancer Res. 2020;80(8):1615–1623. doi:10.1158/0008-5472.CAN-19-2948
   PubMed Web of Science ®Google Scholar
• Fay EK, Graff JN. Immunotherapy in prostate cancer. Cancers. 2020;12(7):1752. doi:10.3390/cancers12071752
   PubMed Web of Science ®Google Scholar
• Hansen AR, Massard C, Ott PA, et al. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol. 2018;29(8):1807–1813. doi:10.1093/annonc/mdy232
   PubMed Web of Science ®Google Scholar
• Passaro A, Stenzinger A, Peters S. Tumor mutational burden as a pan-cancer biomarker for immunotherapy: the limits and potential for convergence. Cancer Cell. 2020;38(5):624–625. doi:10.1016/j.ccell.2020.10.019
   PubMed Web of Science ®Google Scholar
• Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808–1825. doi:10.1158/2159-8290.CD-20-0522
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853–861. doi:10.1016/j.ccell.2018.04.001
   PubMed Web of Science ®Google Scholar
• Klein O, Kee D, Markman B, et al. Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. Cancer Cell. 2021;39(5):592–593. doi:10.1016/j.ccell.2021.04.005
   PubMed Web of Science ®Google Scholar
• Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, Phase 2 trial. Lancet. 2016;387(10031):1909–1920. doi:10.1016/S0140-6736(16)00561-4
   PubMed Web of Science ®Google Scholar
• Chan TA, Wolchok JD, Snyder A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2015;373(20):1984. doi:10.1056/NEJMc1508163
   PubMed Web of Science ®Google Scholar
• de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091–2102. doi:10.1056/NEJMoa1911440
   PubMed Web of Science ®Google Scholar
• Claessens F, Visakorpi T. Endocrinology of prostate cancer. Mol Cell Endocrinol. 2018;462(Pt A):1–2. doi:10.1016/j.mce.2018.01.005
   PubMed Web of Science ®Google Scholar
• Shalapour S, Font-Burgada J, Di Caro G, et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature. 2015;521(7550):94–98. doi:10.1038/nature14395
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, Lobert L, Tanner K, et al. Natural killer t-cell immunotherapy in combination with chemotherapy-induced immunogenic cell death targets metastatic breast cancer. Cancer Immunol Res. 2017;5(12):1086–1097. doi:10.1158/2326-6066.CIR-17-0229
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015;3(5):436–443. doi:10.1158/2326-6066.CIR-15-0064
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Gabrilovich DI. Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer. Cancer Immunol Immunother. 2011;60(3):419–423. doi:10.1007/s00262-010-0930-1
   PubMed Web of Science ®Google Scholar
• Hurwitz M. Chemotherapy in prostate cancer. Curr Oncol Rep. 2015;17(10):44. doi:10.1007/s11912-015-0468-7
   PubMed Web of Science ®Google Scholar